Impact of DPP-4 Inhibitors on Interleukin Levels in Type 2 Diabetes Mellitus
Pooled result · IL-6 concentrationResult — go to the resultEstimate −0.54 pg/mL 95% CI −0.82 to −0.25Authors' conclusion
DPP-4i favorably decreased IL-6 levels in patients with T2DM. The impact of DPP-4i on IL-1β and IL-18 needed to be explored with more studies. Further trials should be performed to elucidate this anti-inflammatory effect of DPP-4i during treatment of T2DM.
Study context
- Population
- Patients with T2D in randomized controlled trials (RCTs) reporting changes of interleukins during DPP-4i treatment; PubMed, Embase, Cochrane library to May 31, 2024
- Participants
- 850 patients14 RCTs
- Comparison
- DPP-4i vs placebo
- Outcome
- IL concentrations
Methodological detailsplacebo- or active agents-controlled
- Placebo- or active agents-controlled
Pooled result
IL-6 concentration
Estimate
−0.54 pg/mL
95% CI −0.82 to −0.25
P = 0.0003
As reported in the abstract
Further pooled results
| Outcome | pg/mL | P value |
|---|---|---|
| IL-1β concentrationI2 = 0% | −16.33 (95% CI −19.56 to −13.11) | P < 0.00001 |
| IL-18 concentrationI2 = 0%; not statistically significant | −13.55 (95% CI −76.95 to 49.85) | P = 0.68 |
IL-6 subgroup analysis
- Marked effects on IL-6 in subgroups with basal IL-6 < 5 pg/mL, BMI ≥ 28 kg/m² and linagliptin
Original publication
Impact of DPP-4 Inhibitors on Interleukin Levels in Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. Published 8 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →